Based on the Arcturus Therapeutics Holdings Inc stock forecast from 5 analysts, the average analyst target price for Arcturus Therapeutics Holdings Inc is USD 46.00 over the next 12 months. Arcturus Therapeutics Holdings Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Arcturus Therapeutics Holdings Inc is Slightly Bearish, which is based on 4 positive signals and 5 negative signals. At the last closing, Arcturus Therapeutics Holdings Inc’s stock price was USD 10.57. Arcturus Therapeutics Holdings Inc’s stock price has changed by +18.63% over the past week, -24.93% over the past month and -64.92% over the last year.
No recent analyst target price found for Arcturus Therapeutics Holdings Inc
No recent average analyst rating found for Arcturus Therapeutics Holdings Inc
Company Overview Arcturus Therapeutics Holdings Inc
Arcturus Therapeutics Holdings Inc. engages in the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms includes LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate that is in phase 2 clinical trial for cystic fibrosis. Its product pipeline includes KOSTAIVE for the treatment of covid 19; ARCT-2138 (LUNAR-FLU), which is in phase 1 clinical trial for the treatment of seasonal influenza; ARCT-2304 (LUNAR-H5N1) that is in phase 1 clinical trial for the treatment of Pandemic Influenza; ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3 clinical trial; and ARCT-2303 for monovalent that is in Phase 3 clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California. Read Less
Arcturus Therapeutics Holdings Inc. engages in the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms includes LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-O...Read More
Frequently Asked Questions About Arcturus Therapeutics Holdings Inc (ARCT) Stock
Based on ratings from 5 analysts Arcturus Therapeutics Holdings Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 10 buy, sell and hold ratings.
Unfortunately we do not have enough data on ARCT's stock to indicate if its a good dividend stock.
Based on targets from 5 analysts, the average taret price for ARCT is USD 46.00 over the next 12 months. The maximum analyst target price is USD 50 while the minimum anlayst target price is USD 41.
ARCT stock's Price/Earning ratio is 10.30.
Our analysis grades ARCT stock's Price / Earning ratio at F. This means that ARCT stock's Price/Earning ratio is above 59.00000000000001% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this ARCT may be a overvalued for its sector.
The last closing price of ARCT's stock was USD 10.57.
The most recent market capitalization for ARCT is USD 0.26B.
Based on targets from 5 analysts, the average taret price for ARCT is projected at USD 46.00 over the next 12 months.
This means that ARCT's stock price may go up by +335.19% over the next 12 months.
We can't find any ETFs which contains Arcturus Therapeutics Holdings Inc's stock.
As per our most recent records Arcturus Therapeutics Holdings Inc has 174 Employees.
Arcturus Therapeutics Holdings Inc's registered address is 10628 Science Center Drive, San Diego, CA, United States, 92121.
You can get more information about it from Arcturus Therapeutics Holdings Inc's website at https://arcturusrx.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Arcturus Therapeutics Holdings Inc (ARCT) Stock
Based on ratings from 5 analysts Arcturus Therapeutics Holdings Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 10 buy, sell and hold ratings.
Unfortunately we do not have enough data on ARCT's stock to indicate if its a good dividend stock.
Based on targets from 5 analysts, the average taret price for ARCT is USD 46.00 over the next 12 months. The maximum analyst target price is USD 50 while the minimum anlayst target price is USD 41.
ARCT stock's Price/Earning ratio is 10.30.
Our analysis grades ARCT stock's Price / Earning ratio at F. This means that ARCT stock's Price/Earning ratio is above 59.00000000000001% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this ARCT may be a overvalued for its sector.
The last closing price of ARCT's stock was USD 10.57.
The most recent market capitalization for ARCT is USD 0.26B.
Based on targets from 5 analysts, the average taret price for ARCT is projected at USD 46.00 over the next 12 months.
This means that ARCT's stock price may go up by +335.19% over the next 12 months.
We can't find any ETFs which contains Arcturus Therapeutics Holdings Inc's stock.
As per our most recent records Arcturus Therapeutics Holdings Inc has 174 Employees.
Arcturus Therapeutics Holdings Inc's registered address is 10628 Science Center Drive, San Diego, CA, United States, 92121.
You can get more information about it from Arcturus Therapeutics Holdings Inc's website at https://arcturusrx.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for ARCT !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
